[Non-culturable Koch bacilli during antitubercular chemotherapy]. 1977

V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar

The authors have performed 58435 microscopic examinations, of which 3813 were positive, and found 209 (5,48%) cases of non-cultivable Koch bacilli. The major bacteriological, clinico-evolutive and therapeutical aspects are examined. Most of the cases showing a syndrome of positive homogenate with a negative culture were rather recent ones (an evolution of less than 2 years in 73,68% of the total) and the highest frequency was found in those in which the treatment was in its first year. No direct relationship could be demonstrated between the number of germs (the Gaffky scale) and the frequency of the syndrome. The factors influencing the occurrence and the development of the syndrome are: the structure of the lesions, the method of bacteriologic examination, the therapy applied, and a certain immunologic reactivity. According to the authors the significance of this syndrome is positive in most of the cases, indicating a regression that has not been completed. The most reasonable attitude is a differentiated one, depending on each case, integrating the data obtained by the bacteriological examination in the therapeutic and evolutive clinico-radiologic context.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
January 1978, Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
January 1964, Le Poumon et le coeur,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
March 2018, American journal of respiratory and critical care medicine,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
April 1949, Lyon medical,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
October 1952, Journal de medecine de Bordeaux et du Sud-Ouest,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
November 1964, Gruzlica (Warsaw, Poland : 1926),
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
November 1976, Harefuah,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
December 1997, Revue des maladies respiratoires,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
September 1964, Schweizerische medizinische Wochenschrift,
V Moisescu, and E Fanea, and G Petrescu, and M Popescu, and L Rusu, and D Ionescu, and G Ariton, and O Nicoară, and M Molnar
December 1973, Nursing times,
Copied contents to your clipboard!